Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Receives Average Recommendation of “Moderate Buy” from Analysts

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has been given an average recommendation of “Moderate Buy” by the fifteen brokerages that are covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $177.00.

Several analysts have commented on the company. Robert W. Baird raised their price objective on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a report on Monday, November 18th. Morgan Stanley raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $140.00 to $175.00 in a research note on Thursday, December 12th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $179.00 price objective on shares of Jazz Pharmaceuticals in a report on Tuesday, December 10th. Needham & Company LLC reiterated a “buy” rating and issued a $207.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Finally, TD Cowen reduced their price target on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research report on Thursday, November 7th.

Jazz Pharmaceuticals Price Performance

NASDAQ:JAZZ opened at $120.23 on Friday. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals has a 52 week low of $99.06 and a 52 week high of $134.17. The stock’s 50-day moving average price is $121.59 and its 200-day moving average price is $113.94. The stock has a market capitalization of $7.27 billion, a PE ratio of 16.93, a price-to-earnings-growth ratio of 1.04 and a beta of 0.56.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the business’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $110.84, for a total value of $110,840.00. Following the transaction, the chief executive officer now directly owns 428,976 shares in the company, valued at $47,547,699.84. The trade was a 0.23 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Neena M. Patil sold 3,700 shares of the stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $123.41, for a total transaction of $456,617.00. Following the completion of the sale, the executive vice president now directly owns 33,048 shares of the company’s stock, valued at approximately $4,078,453.68. This trade represents a 10.07 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 8,253 shares of company stock valued at $1,001,434. 4.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Large investors have recently modified their holdings of the business. Itau Unibanco Holding S.A. purchased a new stake in Jazz Pharmaceuticals in the 2nd quarter valued at about $29,000. EverSource Wealth Advisors LLC raised its stake in shares of Jazz Pharmaceuticals by 55.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock valued at $30,000 after acquiring an additional 97 shares during the period. GAMMA Investing LLC raised its stake in shares of Jazz Pharmaceuticals by 41.3% in the 3rd quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company’s stock valued at $46,000 after acquiring an additional 121 shares during the period. Venturi Wealth Management LLC boosted its position in shares of Jazz Pharmaceuticals by 577.0% during the 3rd quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock worth $92,000 after purchasing an additional 704 shares during the period. Finally, Versant Capital Management Inc increased its holdings in Jazz Pharmaceuticals by 56.7% in the 4th quarter. Versant Capital Management Inc now owns 967 shares of the specialty pharmaceutical company’s stock valued at $119,000 after purchasing an additional 350 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.